View Financial HealthMapLight Therapeutics 配当と自社株買い配当金 基準チェック /06MapLight Therapeutics配当金を支払った記録がありません。主要情報n/a配当利回り-20.6%バイバック利回り総株主利回り-20.6%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesRecent Insider Transactions Derivative • May 05Founder notifies of intention to sell stockChristopher Kroeger intends to sell 236k shares in the next 90 days after lodging an Intent To Sell Form on the 4th of May. If the sale is conducted around the recent share price of US$30.70, it would amount to US$7.3m. For the year to December 2023, Christopher's total compensation was 3% salary and 97% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2025, Christopher's direct individual holding has increased from 6.02k shares to 325.10k. Company insiders have collectively sold US$674k more than they bought, via options and on-market transactions in the last 12 months.お知らせ • May 04MapLight Therapeutics Announces Completion of Enrollment In Zephyr Phase 2 Trial And Updates Expected Timing of Topline ResultsMapLight Therapeutics, Inc. announced completion of enrollment in its Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia. The Company also announced completion of the final patient visit in its Phase 2 IRIS trial evaluating ML-004 for the treatment of autism spectrum disorder. The Company expects to report topline results from both Phase 2 trials by mid-August 2026. The Phase 2 ZEPHYR trial is a randomized, double-blind, placebo-controlled trial evaluating the efficacy, safety, and tolerability of ML-007C-MA in inpatient adult participants with schizophrenia experiencing an acute exacerbation of psychosis. 307 participants in the trial were randomized 1:1:1 to receive either placebo, ML-007C-MA 210/3 mg twice daily, or ML-007C-MA 330/6 mg once daily. Primary endpoint is the change in PANSS total score from baseline to Week 5. Key secondary endpoints include change in CGI-S score, PANSS-Marder positive and negative factor scores from baseline to Week 5. Exploratory endpoints include change in cognitive function, assessed across multiple domains commonly impacted in schizophrenia, from baseline to Week 5. The Phase 2 IRIS trial is a randomized, double-blind, placebo-controlled trial evaluating the efficacy, safety, and tolerability of ML-004 in adults and adolescents with autism spectrum disorder. 161 participants were randomized in the trial, consistent with enrollment target of over 100 adolescents (aged 12-17). Primary endpoint is the change in Autism Behavioral Inventory (ABI)-Social Communication Domain Score from baseline to Week 12. Key secondary endpoints include change in CGI-I, ABI-C and Aberrant Behavior Checklist-Irritability (ABC-I) score from baseline to Week 12.お知らせ • May 01MapLight Therapeutics, Inc., Annual General Meeting, Jun 23, 2026MapLight Therapeutics, Inc., Annual General Meeting, Jun 23, 2026.Recent Insider Transactions Derivative • Apr 16Founder notifies of intention to sell stockChristopher Kroeger intends to sell 21k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of April. If the sale is conducted around the recent share price of US$27.02, it would amount to US$563k. For the year to December 2023, Christopher's total compensation was 7% salary and 93% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2025, Christopher's direct individual holding has increased from 6.02k shares to 148.86k. Company insiders have collectively sold US$674k more than they bought, via options and on-market transactions in the last 12 months.New Risk • Apr 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 11% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$286m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Significant insider selling over the past 3 months (US$1.4m sold).Recent Insider Transactions • Mar 03Co-Founder recently sold US$260k worth of stockOn the 24th of February, Robert Malenka sold around 14k shares on-market at roughly US$18.34 per share. This transaction amounted to 9.1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth US$636k. Robert has been a net seller over the last 12 months, reducing personal holdings by US$1.4m.Recent Insider Transactions Derivative • Feb 24Co-Founder notifies of intention to sell stockRobert Malenka intends to sell 11k shares in the next 90 days after lodging an Intent To Sell Form on the 23rd of February. If the sale is conducted around the recent share price of US$18.42, it would amount to US$207k. Since September 2025, Robert's direct individual holding has increased from 3.38k shares to 155.74k. Company insiders have collectively sold US$414k more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions • Feb 13Independent Director recently bought US$253k worth of stockOn the 10th of February, Timothy Garnett bought around 14k shares on-market at roughly US$17.89 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$16m more in shares than they have sold in the last 12 months.Recent Insider Transactions Derivative • Feb 12Co-Founder notifies of intention to sell stockRobert Malenka intends to sell 7k shares in the next 90 days after lodging an Intent To Sell Form on the 10th of February. If the sale is conducted around the recent share price of US$18.12, it would amount to US$120k. Since September 2025, Robert's direct individual holding has increased from 3.38k shares to 174.72k. Company insiders have collectively bought US$15m more than they sold, via options and on-market transactions, in the last 12 months.Recent Insider Transactions • Feb 01Co-Founder recently sold US$636k worth of stockOn the 30th of January, Robert Malenka sold around 34k shares on-market at roughly US$18.49 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Robert's only on-market trade for the last 12 months.Recent Insider Transactions Derivative • Jan 29Co-Founder notifies of intention to sell stockRobert Malenka intends to sell 7k shares in the next 90 days after lodging an Intent To Sell Form on the 28th of January. If the sale is conducted around the recent share price of US$18.65, it would amount to US$122k. Since September 2025, Robert's direct individual holding has increased from 3.38k shares to 31.67k. There has only been one transaction (US$16m purchase) from insiders over the last 12 months.お知らせ • Jan 09MapLight Therapeutics, Inc. Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Third Quarter of 2026MapLight Therapeutics, Inc. announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule. The company's Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia continues to enroll robust, and topline results are now expected in the third quarter of 2026. The ZEPHYR study is a randomized, double-blind, placebo-controlled trial that is expected to enroll 300 hospitalized adult participants with schizophrenia experiencing acute exacerbation of psychosis. In addition, following completion of enrollment in the Phase 2 IRIS trial for ML-004 in autism spectrum disorder, topline results for that study are now expected in the third quarter of 2026. The IRIS study is a double-blind, placebo-controlled trial that randomized approximately 160 adult and adolescent participants.お知らせ • Jan 05Maplight Therapeutics, Inc. Receives Fast Track Designation for ML-007C-Ma for Alzheimer's Disease PsychosisMapLight Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel M1/M4 muscarinic agonist, for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). The Fast Track process is intended to facilitate the development and expedite the review of investigational therapies for serious conditions with unmet medical need. A drug with Fast Track designation may be eligible for more frequent interactions with the FDA, as well as accelerated approval and priority review, if applicable criteria are met. In a Phase 1 clinical trial, ML-007C-MA demonstrated a generally favorable safety and tolerability profile with twice daily dosing in healthy elderly participants. Enrollment is currently ongoing in the Phase 2 VISTA study, a randomized, double-blind, placebo-controlled trial evaluating ML-007C-MA for the treatment of hallucinations and delays associated with ADP. MapLight expects to enroll 300 participants in the trial and report topline results in the second half of 2027.Recent Insider Transactions • Nov 02Independent Director recently bought US$16m worth of stockOn the 28th of October, Jim Trenkle bought around 953k shares on-market at roughly US$17.00 per share. This transaction amounted to 35% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Board Change • Oct 28High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. Founder, President, CEO & Director Chris Kroeger is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Oct 27MapLight Therapeutics, Inc. has completed an IPO in the amount of $250.75 million.MapLight Therapeutics, Inc. has completed an IPO in the amount of $250.75 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 14,750,000 Price\Range: $17 Discount Per Security: $1.19 Transaction Features: Reserved Share Offering; Sponsor Backed Offering決済の安定と成長配当データの取得安定した配当: MPLTの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: MPLTの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場MapLight Therapeutics 配当利回り対市場MPLT 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (MPLT)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.4%アナリスト予想 (MPLT) (最長3年)n/a注目すべき配当: MPLTは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: MPLTは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: MPLTの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: MPLTが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 03:33終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MapLight Therapeutics, Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関Sumant Satchidanand KulkarniCanaccord GenuityAdam VogelCraig-Hallum Capital Group LLCRaghuram SelvarajuH.C. Wainwright & Co.7 その他のアナリストを表示
Recent Insider Transactions Derivative • May 05Founder notifies of intention to sell stockChristopher Kroeger intends to sell 236k shares in the next 90 days after lodging an Intent To Sell Form on the 4th of May. If the sale is conducted around the recent share price of US$30.70, it would amount to US$7.3m. For the year to December 2023, Christopher's total compensation was 3% salary and 97% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2025, Christopher's direct individual holding has increased from 6.02k shares to 325.10k. Company insiders have collectively sold US$674k more than they bought, via options and on-market transactions in the last 12 months.
お知らせ • May 04MapLight Therapeutics Announces Completion of Enrollment In Zephyr Phase 2 Trial And Updates Expected Timing of Topline ResultsMapLight Therapeutics, Inc. announced completion of enrollment in its Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia. The Company also announced completion of the final patient visit in its Phase 2 IRIS trial evaluating ML-004 for the treatment of autism spectrum disorder. The Company expects to report topline results from both Phase 2 trials by mid-August 2026. The Phase 2 ZEPHYR trial is a randomized, double-blind, placebo-controlled trial evaluating the efficacy, safety, and tolerability of ML-007C-MA in inpatient adult participants with schizophrenia experiencing an acute exacerbation of psychosis. 307 participants in the trial were randomized 1:1:1 to receive either placebo, ML-007C-MA 210/3 mg twice daily, or ML-007C-MA 330/6 mg once daily. Primary endpoint is the change in PANSS total score from baseline to Week 5. Key secondary endpoints include change in CGI-S score, PANSS-Marder positive and negative factor scores from baseline to Week 5. Exploratory endpoints include change in cognitive function, assessed across multiple domains commonly impacted in schizophrenia, from baseline to Week 5. The Phase 2 IRIS trial is a randomized, double-blind, placebo-controlled trial evaluating the efficacy, safety, and tolerability of ML-004 in adults and adolescents with autism spectrum disorder. 161 participants were randomized in the trial, consistent with enrollment target of over 100 adolescents (aged 12-17). Primary endpoint is the change in Autism Behavioral Inventory (ABI)-Social Communication Domain Score from baseline to Week 12. Key secondary endpoints include change in CGI-I, ABI-C and Aberrant Behavior Checklist-Irritability (ABC-I) score from baseline to Week 12.
お知らせ • May 01MapLight Therapeutics, Inc., Annual General Meeting, Jun 23, 2026MapLight Therapeutics, Inc., Annual General Meeting, Jun 23, 2026.
Recent Insider Transactions Derivative • Apr 16Founder notifies of intention to sell stockChristopher Kroeger intends to sell 21k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of April. If the sale is conducted around the recent share price of US$27.02, it would amount to US$563k. For the year to December 2023, Christopher's total compensation was 7% salary and 93% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2025, Christopher's direct individual holding has increased from 6.02k shares to 148.86k. Company insiders have collectively sold US$674k more than they bought, via options and on-market transactions in the last 12 months.
New Risk • Apr 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 11% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$286m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Significant insider selling over the past 3 months (US$1.4m sold).
Recent Insider Transactions • Mar 03Co-Founder recently sold US$260k worth of stockOn the 24th of February, Robert Malenka sold around 14k shares on-market at roughly US$18.34 per share. This transaction amounted to 9.1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth US$636k. Robert has been a net seller over the last 12 months, reducing personal holdings by US$1.4m.
Recent Insider Transactions Derivative • Feb 24Co-Founder notifies of intention to sell stockRobert Malenka intends to sell 11k shares in the next 90 days after lodging an Intent To Sell Form on the 23rd of February. If the sale is conducted around the recent share price of US$18.42, it would amount to US$207k. Since September 2025, Robert's direct individual holding has increased from 3.38k shares to 155.74k. Company insiders have collectively sold US$414k more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions • Feb 13Independent Director recently bought US$253k worth of stockOn the 10th of February, Timothy Garnett bought around 14k shares on-market at roughly US$17.89 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$16m more in shares than they have sold in the last 12 months.
Recent Insider Transactions Derivative • Feb 12Co-Founder notifies of intention to sell stockRobert Malenka intends to sell 7k shares in the next 90 days after lodging an Intent To Sell Form on the 10th of February. If the sale is conducted around the recent share price of US$18.12, it would amount to US$120k. Since September 2025, Robert's direct individual holding has increased from 3.38k shares to 174.72k. Company insiders have collectively bought US$15m more than they sold, via options and on-market transactions, in the last 12 months.
Recent Insider Transactions • Feb 01Co-Founder recently sold US$636k worth of stockOn the 30th of January, Robert Malenka sold around 34k shares on-market at roughly US$18.49 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Robert's only on-market trade for the last 12 months.
Recent Insider Transactions Derivative • Jan 29Co-Founder notifies of intention to sell stockRobert Malenka intends to sell 7k shares in the next 90 days after lodging an Intent To Sell Form on the 28th of January. If the sale is conducted around the recent share price of US$18.65, it would amount to US$122k. Since September 2025, Robert's direct individual holding has increased from 3.38k shares to 31.67k. There has only been one transaction (US$16m purchase) from insiders over the last 12 months.
お知らせ • Jan 09MapLight Therapeutics, Inc. Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Third Quarter of 2026MapLight Therapeutics, Inc. announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule. The company's Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia continues to enroll robust, and topline results are now expected in the third quarter of 2026. The ZEPHYR study is a randomized, double-blind, placebo-controlled trial that is expected to enroll 300 hospitalized adult participants with schizophrenia experiencing acute exacerbation of psychosis. In addition, following completion of enrollment in the Phase 2 IRIS trial for ML-004 in autism spectrum disorder, topline results for that study are now expected in the third quarter of 2026. The IRIS study is a double-blind, placebo-controlled trial that randomized approximately 160 adult and adolescent participants.
お知らせ • Jan 05Maplight Therapeutics, Inc. Receives Fast Track Designation for ML-007C-Ma for Alzheimer's Disease PsychosisMapLight Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel M1/M4 muscarinic agonist, for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). The Fast Track process is intended to facilitate the development and expedite the review of investigational therapies for serious conditions with unmet medical need. A drug with Fast Track designation may be eligible for more frequent interactions with the FDA, as well as accelerated approval and priority review, if applicable criteria are met. In a Phase 1 clinical trial, ML-007C-MA demonstrated a generally favorable safety and tolerability profile with twice daily dosing in healthy elderly participants. Enrollment is currently ongoing in the Phase 2 VISTA study, a randomized, double-blind, placebo-controlled trial evaluating ML-007C-MA for the treatment of hallucinations and delays associated with ADP. MapLight expects to enroll 300 participants in the trial and report topline results in the second half of 2027.
Recent Insider Transactions • Nov 02Independent Director recently bought US$16m worth of stockOn the 28th of October, Jim Trenkle bought around 953k shares on-market at roughly US$17.00 per share. This transaction amounted to 35% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Board Change • Oct 28High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. Founder, President, CEO & Director Chris Kroeger is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Oct 27MapLight Therapeutics, Inc. has completed an IPO in the amount of $250.75 million.MapLight Therapeutics, Inc. has completed an IPO in the amount of $250.75 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 14,750,000 Price\Range: $17 Discount Per Security: $1.19 Transaction Features: Reserved Share Offering; Sponsor Backed Offering